The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patientsSin categoríaJuly 25, 2025
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsSin categoríaMay 28, 2025
